A Phase 1, Parallel, Randomized, Multi-center Study to Evaluate the Safety and Immunogenicity of Different LNP Formulations of mRNA Vaccines Using the RSV Monovalent Antigen in Healthy Participants 18 to 49 Years of Age
Latest Information Update: 28 Jul 2025
At a glance
- Drugs SP 0256
- Indications Metapneumovirus infections; Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi
Most Recent Events
- 28 Jul 2025 New trial record